

# Damon E Houghton

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5298874/publications.pdf>

Version: 2024-02-01

57  
papers

991  
citations

687363  
13  
h-index

454955  
30  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1399  
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 411-421.	3.8	381
2	Anticoagulation in COVID-19: A Systematic Review, Meta-analysis, and Rapid Guidance From Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2467-2486.	3.0	91
3	Testosterone therapy and venous thromboembolism: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2018, 172, 94-103.	1.7	52
4	Thromboinflammatory Biomarkers in COVID-19: Systematic Review and Meta-analysis of 17,052 Patients. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 388-402.	2.4	51
5	Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. <i>American Journal of Hematology</i> , 2019, 94, 1185-1192.	4.1	44
6	Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort. <i>Leukemia and Lymphoma</i> , 2017, 58, 2573-2581.	1.3	34
7	Apixaban and Rivaroxaban in Patients With Acute Venous Thromboembolism. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1242-1252.	3.0	26
8	Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. <i>European Journal of Haematology</i> , 2020, 104, 88-96.	2.2	24
9	Timing of venous thromboembolism diagnosis in hospitalized and non-hospitalized patients with COVID-19. <i>Thrombosis Research</i> , 2021, 207, 150-157.	1.7	24
10	Risk of venous thromboembolism after COVID-19 vaccination. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1638-1644.	3.8	24
11	Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. <i>American Journal of Hematology</i> , 2020, 95, 817-823.	4.1	20
12	Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2793-2805.	3.0	20
13	Effectiveness and safety of apixaban and rivaroxaban for acute venous thromboembolism therapy in patients with extremes in bodyweight. <i>European Journal of Haematology</i> , 2020, 105, 484-494.	2.2	19
14	Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC). <i>ELife</i> , 2020, 9, .	6.0	19
15	Hemoglobin levels and coronary heart disease risk by age, race, and sex in the reasons for geographic and racial differences in stroke study (REGARDS). <i>American Journal of Hematology</i> , 2020, 95, 258-266.	4.1	14
16	Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-Wide Sample of Hospitalized COVID-19-Positive Compared With COVID-19-Negative Patients. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1718-1726.	3.0	11
17	Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2206-2215.	3.8	11
18	Adverse Events and Mortality in Anticoagulated Patients with Different Categories of Pulmonary Embolism. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2020, 4, 249-258.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. <i>Blood Advances</i> , 2021, 5, 2807-2812.	5.2	10
20	Calf muscle pump function as a predictor of all-cause mortality. <i>Vascular Medicine</i> , 2020, 25, 519-526.	1.5	9
21	Reduced calf muscle pump function is a risk factor for venous thromboembolism: a population-based cohort study. <i>Blood</i> , 2021, 137, 3284-3290.	1.4	9
22	Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 199-205.	2.1	8
23	Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. <i>Thrombosis Research</i> , 2021, 202, 155-161.	1.7	8
24	Artificial intelligence for the evaluation of peripheral artery disease using arterial Doppler waveforms to predict abnormal ankle-brachial index. <i>Vascular Medicine</i> , 2022, 27, 333-342.	1.5	8
25	Calf Vein Thrombosis Outcomes Comparing Anticoagulation and Serial Ultrasound Imaging Management Strategies. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1184-1192.	3.0	7
26	Thrombosis of atypical location: how to treat patients in the era of direct oral anticoagulants?. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 604-608.	0.4	7
27	Antiphospholipid antibodies. <i>Vascular Medicine</i> , 2017, 22, 545-550.	1.5	6
28	Leukocytosis due to markedly elevated granulocyte-colony stimulating factor levels in a patient with endometrial cancer: Case report and literature review. <i>Gynecologic Oncology Reports</i> , 2017, 20, 5-8.	0.6	5
29	Evaluation of soluble fibrin monomer complex in patients in SARSâ€CoVâ€2 COVIDâ€19 infectionâ€associated coagulopathy. <i>European Journal of Haematology</i> , 2022, 108, 319-326.	2.2	5
30	Single versus multiple and incidental versus symptomatic subsegmental pulmonary embolism: clinical characteristics and outcome. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 82-90.	2.1	5
31	Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12500.	2.3	4
32	Peripheral Blood Cytopenia and Risk of Cardiovascular Disease and Mortality. <i>Journal of the American Heart Association</i> , 2021, 10, e020809.	3.7	3
33	Optimal Timing for Removal of an Upper Extremity Central Catheter When Associated with a Deep Vein Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. <i>Blood</i> , 2019, 134, 325-325.	1.4	3
34	Pulmonary artery capacitance and pulmonary vascular resistance as prognostic indicators in acute pulmonary embolism. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	3
35	Perils in the thrombophilia workup: Frequency and circumstances of erroneously ordered factor V activity tests for thrombophilia. <i>Vascular Medicine</i> , 2017, 22, 527-528.	1.5	2
36	Venous Thromboembolism Prophylaxis: Need for Continuous Assessment Due to Changes in Risk During the Same Hospitalization. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2020, 4, 170-175.	2.4	2

#	ARTICLE	IF	CITATIONS
37	Prophylactic placement of inferior vena cava filters and the risk of death or venous thromboembolism in severe trauma patients: a retrospective study comparing two hospitals with different approaches. <i>Acta Radiologica Open</i> , 2021, 10, 205846012199934.	0.6	2
38	Treatment of Upper Extremity Deep Vein Thrombosis with Apixaban and Rivaroxaban. <i>Blood</i> , 2019, 134, 2158-2158.	1.4	2
39	Treatment of Venous Thromboembolism in Patients with Hematological Malignancies and Severe Thrombocytopenia: A Retrospective Cohort Analysis. <i>Blood</i> , 2016, 128, 531-531.	1.4	2
40	Evaluation of Changing Vena Cava Filter Use and Inpatient Hospital Mortality from 2016-2019: A Single-Institution Quality Improvement Project. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 851-858.	2.4	1
41	Incidental Pulmonary Embolism. Analysis of Mayo Clinic Venous Thromboembolism Database. <i>Blood</i> , 2019, 134, 1147-1147.	1.4	1
42	Anticoagulants for Hospitalized Patients With COVID-19: The Year of Randomized Controlled Trials. , 2022, 19, .		1
43	Prevalence, Indications, and Outcomes of Stacked Vena Cava Filters. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 800-802.	2.0	0
44	What Is the Price of Preventing COVID-19 Infection? Rare Thrombotic/Thrombocytopenic Events Reported After Vaccination. , 2021, 18, .		0
45	Demographics and Clinical Outcomes in Patients Older Than 75 Years Treated for Acute Venous Thromboembolism. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, e151-e153.	0.9	0
46	Does prophylactic inferior vena cava filter reduce the hazard of pulmonary embolism and mortality in severe trauma? A single center retrospective comparative study. <i>European Journal of Radiology Open</i> , 2021, 8, 100299.	1.6	0
47	The More the Better? Optimal Aspirin Dosing in Patients With Atherosclerotic Disease. , 2021, 18, .		0
48	Weighing the Risk and Benefits of Direct Oral Anticoagulants in Morbidly Obese Patients: New Data and Guidance. , 2021, 18, .		0
49	Association of Pre-Allogeneic Hematopoietic Stem Cell Transplant 25-Hydroxy-Vitamin D Level and Development of Acute Skin Graft-Versus-Host-Disease: A Retrospective Analysis of 154 Patients. <i>Blood</i> , 2016, 128, 5777-5777.	1.4	0
50	Peripheral Blood Cytopenia and Subsequent Risk of Cardiovascular Disease and Mortality. <i>Blood</i> , 2019, 134, 5002-5002.	1.4	0
51	More Options for Cancer-associated Thrombosis: Apixaban Non-inferior to Dalteparin. , 2020, 17, .		0
52	An Inpatient COVID-19 Prophylaxis Protocol and Its Outcomes: Adherence and Efficacy. <i>Blood</i> , 2021, 138, 4267-4267.	1.4	0
53	Acute Deep Vein Thrombosis and Association with Popliteal Fossa (Baker's) Cysts in Patients with Lower Extremity Duplex Ultrasound Examination. <i>Blood</i> , 2020, 136, 9-10.	1.4	0
54	Reduced Calf Muscle Pump Function Is a Risk Factor for Venous Thromboembolism and Mortality. <i>Blood</i> , 2020, 136, 6-7.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Defining Optimal Management of Patients With Intermediate-risk Pulmonary Emboli. , 2022, 19, .		0
56	What's JAK'ing Up the Risk of Cancer and Thromboembolism?. , 2022, 19, .		0
57	Putting the Novel Back in Oral Anticoagulants: Phase II Results of the Factor Xla Inhibitor Asundexian. , 2022, 19, .		0